Edition:
United States

MacroGenics Inc (MGNX.OQ)

MGNX.OQ on NASDAQ Stock Exchange Global Select Market

18.19USD
12:45pm EST
Change (% chg)

$-0.51 (-2.75%)
Prev Close
$18.71
Open
$18.71
Day's High
$19.15
Day's Low
$18.18
Volume
44,785
Avg. Vol
92,783
52-wk High
$26.99
52-wk Low
$14.36

Chart for

About

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology... (more)

Overall

Beta: 2.76
Market Cap(Mil.): $688.95
Shares Outstanding(Mil.): 36.82
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 185.97 15.71
EPS (TTM): -- -- --
ROI: -- -11.84 31.93
ROE: -- -36.93 16.16

BRIEF-Macrogenics- increased number of directors that constitute board from eight to nine ​

* Macrogenics- increased number of directors that constitute board from eight to nine after approving appointment of Jay Siegel on Nov 13 - SEC filing ​ Source text: (http://bit.ly/2A2CHjE) Further company coverage:

Nov 16 2017

BRIEF-Macrogenics names Jay Siegel to its board of directors

* Macrogenics names Jay Siegel to its board of directors Source text for Eikon: Further company coverage:

Nov 15 2017

BRIEF-Macrogenics Posts Q3 loss of $1.28 per share

* Macrogenics provides update on corporate progress and third quarter 2017 financial results

Nov 08 2017

BRIEF-Incyte and MacroGenics announce global collaboration and licensing agreement

* Incyte and MacroGenics announce global collaboration and licensing agreement for Anti-PD-1 Monoclonal Antibody MGA012

Oct 25 2017

BRIEF-Macrogenics advances two clinical DART molecules

* Macrogenics advances two first-in-class clinical DART molecules

Sep 05 2017

BRIEF-Macrogenics announces termination of duvortuxizumab collaboration

* Macrogenics announces termination of duvortuxizumab collaboration and license agreement with Janssen

Aug 31 2017

BRIEF-MacroGenics Q2 net loss per share $1.14

* MacroGenics provides update on corporate progress and second quarter 2017 financial results

Aug 02 2017

BRIEF-Boxer Capital reports 5.5 pct passive stake in Macrogenics

* Boxer Capital, Llc reports 5.5 percent passive stake in Macrogenics Inc as of may 31, 2017 -sec filing Source text - http://bit.ly/2sVCckL Further company coverage:

Jun 12 2017

Competitors

  Price Chg
Roche Holding Ltd. (ROG.S) CHF241.70 +1.10
Roche Holding Ltd. (RO.S) CHF244.00 +0.80
Amgen, Inc. (AMGN.OQ) $176.25 -0.58
Xencor Inc (XNCR.OQ) $20.87 -0.75

Earnings vs. Estimates